| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/14/2004 | US6790859 Therapy or reducing progression of hypertension or damage to a tissue caused by contact with elevated levels of reducing sugars in an animal, comprising administering to the animal an effective amount of thiazolium compounds |
| 09/14/2004 | US6790850 Thiazolo(4,5-d)pyrimidine compounds |
| 09/14/2004 | US6790823 Compositions and methods for the prevention and treatment of cardiovascular diseases |
| 09/14/2004 | US6790639 Bone morphogenic proteins; for regulating bone homeostasis, adiposity, and calcification of atherosclerotic plaques |
| 09/14/2004 | US6790463 Peroxidation reaction products of an alkene, such as geraniol; penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. |
| 09/14/2004 | US6790443 Administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts |
| 09/14/2004 | CA2315826C Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 09/14/2004 | CA2280708C Cetp activity inhibitors |
| 09/11/2004 | CA2458288A1 Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure |
| 09/10/2004 | WO2004076482A1 Soluble factor secreted by endothelial cells in blood vessels |
| 09/10/2004 | WO2004076476A1 Glycopeptide and use thereof as proteoglycan initiator |
| 09/10/2004 | WO2004076442A1 Polymorphs of losartan |
| 09/10/2004 | WO2004076441A1 Process for producing acid adduct salt of polyacidic base compound |
| 09/10/2004 | WO2004076428A1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
| 09/10/2004 | WO2004076427A1 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis |
| 09/10/2004 | WO2004076426A1 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
| 09/10/2004 | WO2004076406A2 Losartan potassium polymorphs and process for the preparation thereof |
| 09/10/2004 | WO2004075898A1 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| 09/10/2004 | WO2004075893A1 Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker |
| 09/10/2004 | WO2004075892A2 Combination therapy for hypertension using lercanidipine and an angiotensin ii receptor blocker |
| 09/10/2004 | WO2004075889A1 Process for preparation of perindopril and salts thereof |
| 09/10/2004 | WO2004075886A1 Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
| 09/10/2004 | WO2004075884A1 Therapeutic compositions |
| 09/10/2004 | WO2004075856A2 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases |
| 09/10/2004 | WO2004060362A3 COMPOSITIONS AND METHODS FOR INHIBITING TGF-β |
| 09/10/2004 | WO2004052847A3 Tricyclic steroid hormone nuclear receptor modulators |
| 09/10/2004 | WO2004022523A3 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| 09/10/2004 | WO2004022128A3 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
| 09/10/2004 | WO2004017920B1 Novel biphenyl and biphenyl-like cannabinoids |
| 09/10/2004 | WO2004014352A3 Methods for treating carbonic anhydrase mediated disorders |
| 09/10/2004 | WO2003106970A3 P27 prevents cellular migration |
| 09/10/2004 | WO2003090671A3 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 09/10/2004 | WO2003070897A3 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 09/10/2004 | WO2003061652A8 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 09/10/2004 | WO2003003979A3 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 09/10/2004 | WO2002097053A3 Small molecule antagonists of bcl2 family proteins |
| 09/10/2004 | WO2002094780A3 Kinases and phosphatases |
| 09/10/2004 | WO2002064085A3 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 09/10/2004 | CA2517416A1 Therapeutic compositions |
| 09/10/2004 | CA2517386A1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
| 09/10/2004 | CA2517381A1 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis |
| 09/10/2004 | CA2516730A1 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases |
| 09/10/2004 | CA2516620A1 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
| 09/10/2004 | CA2516418A1 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| 09/10/2004 | CA2514948A1 Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
| 09/09/2004 | US20040177388 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 09/09/2004 | US20040176606 Salt formation with benzooic acid in dilluent or carrier for heart disease and hypotensive agents |
| 09/09/2004 | US20040176473 Methods for delivering compounds into a cell |
| 09/09/2004 | US20040176456 Method of treatment for sexual dysfunction |
| 09/09/2004 | US20040176451 Pparg agonistic medicinal compositions |
| 09/09/2004 | US20040176450 Formoterol tartrate polymorph |
| 09/09/2004 | US20040176446 Substituted amino dicarboxylic acid derivatives |
| 09/09/2004 | US20040176444 Phenylalkyloxy-phenyl derivatives |
| 09/09/2004 | US20040176437 Novel compounds for treatment of cardiac arrhythmia, synthesis, and methods of use |
| 09/09/2004 | US20040176436 Tryptophanyl-esters and their N-acyl derivatives for preventing and treating diseases caused or aggravated by oxidation processes |
| 09/09/2004 | US20040176433 treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis |
| 09/09/2004 | US20040176428 treatment of Type 2 diabetes mellitus, obesity and lipid disorders; coadministration with HMG CoA reductase inhibitors |
| 09/09/2004 | US20040176427 Alpha type human peroxisome proliferator activated receptor agonists; such as 2-methyl-2-(3-methyl-4-(((4-phenoxymethyl-2-(4-trifluoromethylphenyl) -thiazol-5-yl-carbonyl)-amino)-methyl)phenoxy)propionic acid |
| 09/09/2004 | US20040176422 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 09/09/2004 | US20040176421 such as 1,4-Bis-{N-[3-(3-aminomethylphenylproplonyl)-2-methoxycarbonylpyrrolidin-4-yl]aminocarbonyloxy}-2-butyne dihydrochloride; for treatment of asthma, allergic conjunctivitis, allergic rhinitis, psoriasis, and ulcerative colitis |
| 09/09/2004 | US20040176418 protease activated receptor (PAR) antagonists will be useful in the treatment of thrombotic, inflammatory, atherosclerotic and fibroproliferative disorders |
| 09/09/2004 | US20040176417 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 09/09/2004 | US20040176411 especially useful for treating asthma and/or rhinitis; example compound N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide |
| 09/09/2004 | US20040176406 Pyrido [2,1-a] isoquinoline derivatives |
| 09/09/2004 | US20040176400 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| 09/09/2004 | US20040176389 Piperazine oxime dervatives having nk-1 receptor antagonistic activity |
| 09/09/2004 | US20040176386 Compounds |
| 09/09/2004 | US20040176383 similar therapeutic properties to ranolazine, but are more potent and have a longer half-life; fatty acid oxidation inhibitor; treatment of diabetes, damage to skeletal muscles resulting from trauma or shock and cardiovascular disease |
| 09/09/2004 | US20040176382 treatment of inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease; |
| 09/09/2004 | US20040176379 agonist effect from one or more of a somatostatin subtype receptor; diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X; inhibiting the proliferation of helicobacter pylori |
| 09/09/2004 | US20040176376 Pyrazolotriazines as CRF antagonists |
| 09/09/2004 | US20040176365 1,8-Naphthyridin-2(1H)-one derivatives; antiasthmatic, antihistamine, and bronchodilator agents; nontoxic, side effect reduction |
| 09/09/2004 | US20040176364 Aryl substituted thiazinidinones and the use thereof |
| 09/09/2004 | US20040176363 N-Acylpiperazine derivatives; cardiovascular disorders; anticoagulants |
| 09/09/2004 | US20040176361 2H-Isoquinolin-1-one derivatives as poly/ADP-ribose/ polymerase inhibitors |
| 09/09/2004 | US20040176356 4-(Hydroxyalkyl-)-piperazinyl(thio)acetamide derivatives for treatment of cardiovascular disorders; antiarrhythmia agents; intermittent claudication, angina, congestive heart failure and myocardial infarction |
| 09/09/2004 | US20040176347 Synergistic mixture of astrocyte function-improving agent and tissue plasminogen activator thrombolytic agent |
| 09/09/2004 | US20040176327 Use of bisphosphonic acids for treating angiogenesis |
| 09/09/2004 | US20040176324 Derivatives of 4,7-ethanothiopyrano[3,4-c]pyrrole-1,3-(2H)-dione, 4,7-epoxy-1H-isoindole-1,3(2H)-dione, and/or 4,7-ethano-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives; autoimmune diseases; anticarcinogenic agents |
| 09/09/2004 | US20040176323 Pharmaceutical composition comprising lysophophatidic acid |
| 09/09/2004 | US20040176320 Use of at least one glycoinhibitor substance |
| 09/09/2004 | US20040176288 Treatment and composition for wound healing |
| 09/09/2004 | US20040176286 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 09/09/2004 | US20040176279 Flint glycoforms |
| 09/09/2004 | US20040176275 Pharmaceutical composition for alleviating tissue hypoxia and methods for alleviating tissue hypoxia |
| 09/09/2004 | US20040176274 Analgesic methods using endothelin receptor ligands |
| 09/09/2004 | US20040176252 Well tolerated; intracellularly increasing cAMP; antiasthmatics, antiinflammatories: regulation of eosinophiles activation and degranulation |
| 09/09/2004 | US20040175703 to be administered by inhalation, infusion, injection, or orally relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference in vitro and in vivo; genetic engineering |
| 09/09/2004 | US20040175424 Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same |
| 09/09/2004 | US20040175419 controlling crystallization parameters of active ingredient to achieve increased compactability; compacting the active ingredient into a tablet |
| 09/09/2004 | US20040175378 Monoclonal antibody 3G4, or an antigen-binding region or immunoconjugate thereof, produced by hybridoma ATCC PTA 4545; binds to phosphatidyl serine |
| 09/09/2004 | US20040175363 Defective recombinant adenovirus; treatment of neurodenerative, cardiovascular, brain, genetic, nervous system and respiratory system disorders; Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), atherosclerosis, and/or trisomy 2; adult respiratory distress syndrome; anticarcinogenic agents |
| 09/08/2004 | EP1454907A1 Quninazoline and pyridopyrmidine derivatives |
| 09/08/2004 | EP1454902A1 N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia |
| 09/08/2004 | EP1454898A1 Novel phenylalanine derivative |
| 09/08/2004 | EP1454897A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY |
| 09/08/2004 | EP1454142A2 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 09/08/2004 | EP1454140A2 Diagnosis and treatment of atherosclerosis |
| 09/08/2004 | EP1454136A2 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 09/08/2004 | EP1453962A2 Inhibitor oligonucleotides and their use for specific repression of a gene |